Opinion|Videos|December 7, 2023

Monitoring Patients With NMIBC

Author(s)Axel Merseburger, MD, PhD, M. Carmen Mir, MD, PhD, Shilpa Gupta, MD, Cleveland Clinic

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Episodes in this series

A panel of 4 experts on bladder cancer seated at a long table

EP. 1 Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

A panel of 4 experts on bladder cancer seated at a long table

EP. 2 Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

A panel of 4 experts on bladder cancer seated at a long table

EP. 3 Monitoring Patients With NMIBC

A panel of 4 experts on bladder cancer seated at a long table

EP. 4 Bladder Cancer: Treatment Options and Managing Adverse Effects

A panel of 4 experts on bladder cancer seated at a long table

EP. 5 Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

A panel of 4 experts on bladder cancer seated at a long table

EP. 6 Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

A panel of 4 experts on bladder cancer seated at a long table

EP. 7 Approach to Collaborative Care in Bladder Cancer

A panel of 4 experts on bladder cancer seated at a long table

EP. 8 Key Takeaways on Evolving Bladder Cancer Treatment Landscape

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

tRCC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

September 14th, 2026

TKI-Based Therapy Is Associated With Improved Disease Control in Metastatic Translocation RCC

TKI-based regimens were associated with higher rates of disease control in metastatic translocation renal cell carcinoma.

Trending on OncLive

FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma

Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL

Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma